Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo NVCMOPF -4.69%79 Cyclically Adjusted PS Ratio is 8.70 as of Jul. 14, 2026, which is 46% below its 10-year median of 16.21. GuruFocus rates CMOPF with a GF Score™ of 79/100 and a GF Value™ of $54.56 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 752 Drug Manufacturers companies, Cosmo NV ranks worse than 89.63% on this metric.
The historical rank and industry rank for Cosmo NV's Cyclically Adjusted PS Ratio or its related term are showing as below:
CMOPF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 5.94 Med: 16.21 Max: 46.43
Current: 9.27
During the past 13 years, Cosmo NV's highest Cyclically Adjusted PS Ratio was 46.43. The lowest was 5.94. And the median was 16.21.
CMOPF's Cyclically Adjusted PS Ratio is ranked worse than 89.63% of 752
companies
in the Drug Manufacturers industry
Industry Median: 1.99
vs CMOPF: 9.27
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Cosmo NV's adjusted revenue per share data of for the fiscal year that ended in Dec25 was $7.638. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $8.76 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Cosmo NV (OTCPK:CMOPF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Cosmo NV Cyclically Adjusted PS Ratio Related Terms
Cosmo NV Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Cosmo NV's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CMOPF vs LLY, JNJ, ABBV: Cyclically Adjusted PS Ratio Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Cosmo NV's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Cosmo NV's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 8.70 mean?
Cosmo NV (CMOPF) has a Cyclically Adjusted PS Ratio of 8.70 as of Jul. 14, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cosmo NV and its competitors. This is 46% below median its historical median of 16.21. Over the past decade, Cosmo NV's Cyclically Adjusted PS Ratio has ranged from 5.94 to 46.43. According to the industry distribution chart, Cosmo NV ranks #674 out of 752 companies in the Drug Manufacturers industry, placing it in the top 89.6%.
Is Cosmo NV's Cyclically Adjusted PS Ratio too high?
Cosmo NV's current Cyclically Adjusted PS Ratio of 8.70 is 46% below median its 10-year median of 16.21. Over the past 10 years, this metric has ranged from a low of 5.94 to a high of 46.43. The Drug Manufacturers industry median Cyclically Adjusted PS Ratio is 1.99. Cosmo NV's value of 8.70 is 337.2% above this industry median. Based on the distribution chart, Cosmo NV ranks #674 out of 752 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cosmo NV has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's Cyclically Adjusted PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #674 out of 752 companies for Cyclically Adjusted PS Ratio. This places Cosmo NV in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 1.99. Cosmo NV's value of 8.70 is 337.2% above this benchmark. Historically, Cosmo NV's own Cyclically Adjusted PS Ratio has ranged from 5.94 to 46.43 over the past decade. While the company's 10-year median is 16.21 vs. the industry median of 1.99, Cosmo NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PS Ratio among Drug Manufacturers companies is 1.99, based on 752 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo NV's current Cyclically Adjusted PS Ratio of 8.70 is 337.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PS Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current Cyclically Adjusted PS Ratio is 8.70, which is 46% below median its own 10-year median of 16.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (CMOPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $54.56, compared to a current price of $76.25 — trading 39.8% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 8.70, which is 46% below median its 10-year median of 16.21 and 337.2% above the Drug Manufacturers industry median of 1.99. Cosmo NV's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Cosmo NV (CMOPF), the current Cyclically Adjusted PS Ratio is 8.70 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (CMOPF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of $76.25 is trading 39.8% above its estimated GF Value™ of $54.56.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for CMOPF:
Cyclically Adjusted PS Ratio: 8.70 (46% below median its 10-year median of 16.21)
GF Value™: $54.56 vs. price of $76.25 (39.8% above fair value)
Industry Position: 337.2% above the Drug Manufacturers median (#674 of 752)
No single metric tells the full story. See the CMOPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
79GF Score
Get the complete analysis for CMOPF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMOPF has been successfully added to your 
